Clinical application of tacrolimus with low-dose prednisone in 21 children with steroid-resistant nephrotic syndrome

OBJECTIVE: To analyze and evaluate the efficacy and safety of tacrolimus and low-dose steroids in the treatment of steroid-resistant nephrotic syndrome in children

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 49(2011), 11 vom: 15. Nov., Seite 825-8
1. Verfasser: Yao, Sheng-hua (VerfasserIn)
Weitere Verfasser: Mao, Jian-hua, Xia, Yong-hui, Wang, Da-yan, Chen, Yi-fang, Fang, Cheng-qing, Liu, Ai-min, Du, Li-zhong
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2011
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Research Support, Non-U.S. Gov't Prednisone VB0R961HZT Tacrolimus WM0HAQ4WNM
LEADER 01000caa a22002652c 4500
001 NLM215436172
003 DE-627
005 20250213162105.0
007 tu
008 231224s2011 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0718.xml 
035 |a (DE-627)NLM215436172 
035 |a (NLM)22336304 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Yao, Sheng-hua  |e verfasserin  |4 aut 
245 1 0 |a Clinical application of tacrolimus with low-dose prednisone in 21 children with steroid-resistant nephrotic syndrome 
264 1 |c 2011 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 10.05.2012 
500 |a Date Revised 07.06.2016 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: To analyze and evaluate the efficacy and safety of tacrolimus and low-dose steroids in the treatment of steroid-resistant nephrotic syndrome in children 
520 |a METHOD: Twenty-one children with steroid-resistant nephrotic syndrome enrolled from October 2008 to July 2010 into this retrospective longitudinal study received oral tacrolimus treatment, 0.1 to 0.15 mg/kg per day and once every 12 hours, and prednisone 0.2 to 0.75 mg/kg per day simultaneously. During the treatment, the plasma concentration of tacrolimus, urine volume, urine, serum creatinine and liver function were regularly monitored 
520 |a RESULT: After 1 to 3 months treatment, 14 cases showed complete remission and 7 cases had partial remission. Sixteen patients received renal biopsy, of whom 6 revealed minimal change nephropathy with complete remission in 3 cases, 3 cases had partial remission;4 cases revealed focal segmental glomerulosclerosis with 2 complete remission and 2 partial remission; other 5 children with IgM nephropathy and 1 mesangial proliferative glomerulonephritis achieved complete remission. Within treatment period, 6 patients presented transient adverse reactions, without altering the principle treatment strategy, but only taking the symptomatic treatment. During follow-up, 1 case was lost to follow-up and the remaining 20 cases were followed up from 2 months to 21 months. In 4 patients the disease relapsed within 1st-year follow-up, while at 2nd-year follow-up, 4 cases had (6 times) recurrence 
520 |a CONCLUSION: Tacrolimus showed a reliable effect in children with steroid-resistant nephrotic syndrome. Less adverse reactions were seen, and most of them could be tolerated. Nevertheless, the patients had a higher relapse rate after 1 to 2 years treatment. Therefore, the long-term effects of tacrolimus for steroid-resistant nephrotic syndrome remains to be further evaluated 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Prednisone  |2 NLM 
650 7 |a VB0R961HZT  |2 NLM 
650 7 |a Tacrolimus  |2 NLM 
650 7 |a WM0HAQ4WNM  |2 NLM 
700 1 |a Mao, Jian-hua  |e verfasserin  |4 aut 
700 1 |a Xia, Yong-hui  |e verfasserin  |4 aut 
700 1 |a Wang, Da-yan  |e verfasserin  |4 aut 
700 1 |a Chen, Yi-fang  |e verfasserin  |4 aut 
700 1 |a Fang, Cheng-qing  |e verfasserin  |4 aut 
700 1 |a Liu, Ai-min  |e verfasserin  |4 aut 
700 1 |a Du, Li-zhong  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 49(2011), 11 vom: 15. Nov., Seite 825-8  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnas 
773 1 8 |g volume:49  |g year:2011  |g number:11  |g day:15  |g month:11  |g pages:825-8 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 49  |j 2011  |e 11  |b 15  |c 11  |h 825-8